Why the Avita (ASX:AVH) share price is charging higher today

The Avita Therapeutics Inc (ASX:AVH) share price is charging higher on Monday. Here's why the Avita share price is on the rise…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Avita Therapeutics Inc (ASX: AVH) share price has started the week in a positive fashion.

The regenerative medicine company's shares are up over 3% to $7.43 in afternoon trade.

Why is the Avita share price charging higher?

The catalyst for today's gain has been the release of an update on its pivotal study assessing the use of the RECELL System to treat stable vitiligo.

The RECELL System is currently used to prepare Spray-On Skin Cells using a small amount of a patient's own skin. This provides a new way to treat severe burns, while significantly reducing the amount of donor skin required.

Avita is aiming to extend its use to treat other unmet medical needs and took a step forward to doing so today. This morning the company announced the initiation of the pivotal vitiligo study following the enrolment of the first patient at the Miami Dermatology and Laser Institute in Florida, United States.

This study will evaluate the safety and effectiveness of the RECELL System to repigment skin in patients who have vitiligo that has been stable for at least one year.

Vitiligo is an autoimmune disease that attacks the epidermis layer of skin. This results in loss of colour or pigmentation. This serious skin condition affects up to 2% of the global population, including an estimated 6.5 million Americans.

There is currently no cure for vitiligo, nor a universally accepted method for limiting the spread of the disease. And while many treatments are being used for its management, they are often temporary with a high rate of recurrence.

A milestone.

The company's CEO, Dr Mike Perry, believes the initiation of the vitiligo clinical study is a milestone in advancing its pipeline to leverage the utility and full potential of the innovative RECELL technology platform to address unmet medical needs in dermatological applications.

Dr Perry commented: "Globally, there have been several published case series and pilot randomized clinical trials reporting positive results with the use of RECELL for treating patients with stable vitiligo and repigmenting depigmented skin lesions. We are pleased to initiate this pivotal study as a next step toward offering a treatment option for the millions of Americans who live with vitiligo."

The Medical Director of Miami Dermatology and Laser Institute, Jill Waibel, MD, spoke positively about the RECELL System's potential.

Waibel said: "While often considered a cosmetic issue, vitiligo can greatly impact the quality of life of those living with the disease, and treatment options are limited. We look forward to assessing the safety and efficacy of the RECELL System in restoring skin colour in stable vitiligo lesions and potentially offering those who live with vitiligo hope with a new, easy in-office treatment."

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Young girl drinking milk showing off muscles.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a great end to the trading week for ASX investors today.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Share Gainers

3 ASX 200 stocks smashing the benchmark this week

These three ASX 200 stocks are leading the charge this week. Here’s how.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why A2 Milk, EOS, GQG, and Mineral Resources shares are racing higher today

These shares are ending the week strongly. But why?

Read more »

A man wearing a red jacket and mountain hiking clothes stands at the top of a mountain peak and looks out over countless mountain ranges.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another disappointing day for ASX investors this Thursday.

Read more »

two men smiling with a laptop in front of them, symbolising a rising share price.
Share Gainers

Why Pinnacle, PWR, Race Oncology, and Vulcan shares are flying today

These shares are having a good session on Thursday. But why?

Read more »

A beautiful woman holds up one finger with one hand and has her hand on her waist with the other as she smiles widely as though she is very pleased about something.
Share Gainers

Why Boss Energy, Emeco, Mineral Resources, and Plenti shares are pushing higher today

These shares are having a good time on hump day. But why?

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Share Gainers

3 ASX 300 shares going gangbusters on Wednesday

Investors are bidding up these three ASX 300 shares today. But why?

Read more »

Man raising both his arms in the air with a piggy bank on his lap, symbolising a record high.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a huge Tuesday for ASX shares, with the index resetting its record high.

Read more »